After 12 weeks of nebulized NAC, patients’ mean phlegm scores, as measured by the COPD assessment test, significantly decreased from 3.47 at baseline to 2.62. N-acetylcysteine (NAC) nebulizer ...

Patients with asthma and COPD routinely switch from pressurized metered-dose inhalers to dry powder inhalers and vice versa.

COPD - Chronic Obstructive Pulmonary Disease - including chronic bronchitis and emphysema, is characterized by breathing difficulty due to partial blockage of the bronchial tubes. Asthma is a ...

This nebulizer has a medication capacity of ... medical conditions like asthma, COPD, bronchodilators. pulmonary fibrosis and ...

Study objectives: To identify the predictors of medication adherence in patients with COPD and contrast the health beliefs, experiences, and behaviors of COPD patients self-reporting good ...

For the 16 million Americans with chronic obstructive pulmonary disease (COPD), travel can be as ... usually use a weekly pill box. Keep a list of these medications with you in a travel folder ...

GSK’s GSK phase III study evaluating its blockbuster drug ... asthma. AstraZeneca is studying Fasenra in late-stage studies for COPD. GSK has a Zacks Rank #3 (Hold). You can see the complete ...

Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into ...

Opens in a new tab or window “Compared to non-CMR recipients, CMR recipients experienced a considerably higher increase in adherence to COPD medications from 2016 to 2017, and findings with data ...

Two posters presented at the CHEST 2024 annual meeting showed that mepolizumab significantly reduces exacerbations in ...

It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis ...

N-acetylcysteine (NAC) nebulizer therapy is effective and safe in the short-term (12 weeks) for reducing phlegm in COPD.